PBM Trade Group Escalates Advocacy Against Drugmakers Following Congressional Overhaul
The leading pharmacy benefit manager lobbying organization is intensifying its advocacy campaign against pharmaceutical manufacturers after Congress enacted comprehensive PBM reform legislation earlier this year. The pharmaceutical industry has long blamed PBMs for high drug costs, culminating in legislative action this past winter. The lobbying escalation suggests ongoing tension between PBMs and drugmakers over responsibility for drug pricing and the implementation of new federal oversight provisions that affect both sectors.
PBM reform implementation will directly affect Medicaid managed care pharmacy contracts, rebate structures, and drug cost transparency requirements that MCOs must navigate with their PBM vendors.
Pharmacy · Managed Care
You might also like